Grazoprevir/ruzasvir/uprifosbuvir

Drug Profile

Grazoprevir/ruzasvir/uprifosbuvir

Alternative Names: MK-3682B; MK-5172/MK-3682/MK-8408; MK3

Latest Information Update: 27 Feb 2017

Price : $50

At a glance

  • Originator Merck & Co
  • Class Antivirals; Macrocyclic compounds; Small molecules; Uracil nucleotides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 01 Dec 2016 Merck completes a phase-II trial in Hepatitis C (Combination therapy, In adults, In the elderly, Treatment-naive) in Australia, Austria, Canada, Denmark, France, Germany, Israel, Italy, Lithuania, New Zealand, Poland, Puerto Rico, Spain, Sweden, United Kingdom and USA (PO) (NCT02332707; EudraCT2014-003304-73)
  • 13 Nov 2016 Efficacy and adverse events data from three phase-II trials in Hepatitis C released by Merck (NCT02332707; NCT02332720; NCT02613403)
  • 11 Nov 2016 Adverse events and efficacy data from a phase II trial in Hepatitis C presented at the 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top